=Eli Lilly (LLY) : lung cancer drug Verzenio failed a late-stage study

Eli Lilly announces that its Phase 3 JUNIPER study evaluating Verzenio, did not meet its primary endpoint of overall survival (OS). 
An analysis of the secondary study endpoints of both progression-free survival (PFS) and overall response rate (ORR) showed evidence of monotherapy activity in the abemaciclib arm. In addition, the control arm showed a higher overall survival rate than expected based on historical data in this setting. Lilly will submit the data for presentation at a medical meeting in 2018.